Poster Session : PS 0033 ; Cardiology : Impact of Metabolic Syndrome and Obesity on Clinical Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction = Poster Session : PS 0033 ; Cardiology : Impact of Metabolic Syndrome and Obesity on Clinical Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

다국어 초록 (Multilingual Abstract)

Background: The correlation between obesity and metabolic syndrome (MetS) remains unclear. This study aims to investigate impact of obesity phenotype on clinical outcomes with ST-segment elevation myocardial infarction (STEMI). Methods: We analyzed in-hospital mortality and major adverse cardiac events (MACE) of 2,606 obese patients who underwent primary percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry from November 2005 to October 2010. Patients were divided into two groups: unhealthy (any of the Mets components) obesity (BMI =25 kg/m2) and healthy (none of the Mets components) obesity. Results: The unhealthy obesity group was composed of 703 patients (27%) and healthy obesity group 1,903 patients (73%). Unhealthy obesity was more frequent in female (25.9% vs. 10.1%, P<0.001) and multi-vessel disease (53.1% vs. 47.6%, P=0.012). There were no signifi cant differences in other baseline characteristics, angiographic and procedural fi ndings, and prescribed medications between two groups. The overall incidence of complications after PCI (13.1% vs. 10.7%, P=0.097) and in-hospital mortality (1.9% vs. 1.6%, P=0.521) were similar in unhealthy obesity group compared with healthy obesity group. By the multivariate Cox regression analyses, the presence of Mets in obese patients was not an independent factor for predicting the adjusted MACE rate at one-month (HR 1.19, 95% CI 0.56-2.54, P=0.645), six-month (HR 1.48, 95% CI 0.94-2.32, P=0.088), and twelve-month (HR 1.10, 95% CI 0.75-1.61, P=0.622). Conclusions: Obesity phenotype is not an independent prognostic factor for patients with STEMI who undergoing primary PCI. The risk stratifi cation by presence or absence of Mets is not useful in these patients.